To evaluate safety, tolerability, and clinical activity of the antibody-drug conjugate, GSK2857916 administered in combination with lenalidomide plus dexamethasone (Arm A), or in combination with bortezomib plus dexamethasone (Arm B) in participants with Relapsed/Refractory Multiple Myeloma (RRMM)

Trial Identifier: 207497
Sponsor: GlaxoSmithKline
Collaborator:
IQVIA
Start Date: September 2018
Primary Completion Date: February 2023
Study Completion Date: February 2024
Condition: Myeloma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Australia, NSW Wollongong, NSW, Australia, 2500
Australia, SA Woodville, SA, Australia, 5011
Australia, VIC Fitzroy, VIC, Australia, 3065
Australia, VIC Melbourne, VIC, Australia, 3004
Australia, VIC Melbourne, VIC, Australia, 3000
Australia, WA Murdoch, WA, Australia, 6150
Australia, WA Nedlands, WA, Australia, 6009
Canada, QC Montreal, QC, Canada, H1T 2M4
Spain Barcelona, Spain, 8035
Spain Madrid, Spain, 28040
Spain Madrid, Spain, 28050
Spain Salamanca, Spain, 37007
United Kingdom London, United Kingdom, W1T 7HA
United Kingdom Truro, United Kingdom, TR1 3LJ
United States, AL Birmingham, AL, United States, 35294
United States, AZ Goodyear, AZ, United States, 85338
United States, GA Atlanta, GA, United States, 30322-4200
United States, IN Indianapolis, IN, United States, 46202
United States, MI Lansing, MI, United States, 48910
United States, MO St Louis, MO, United States, 63110
United States, NE Grand Island, NE, United States, 68803
United States, NJ Hackensack, NJ, United States, 07601
United States, NY Bronx, NY, United States, 10467
United States, NY New York, NY, United States, 10022
United States, SC Greenville, SC, United States, 29650
United States, TX Dallas, TX, United States, 75251